Mazdutide, Survodutide, Retatrutide: Next-Generation Incretin Reference Standards
Two GLP-1/glucagon dual agonists and a GIP/GLP-1/glucagon tri-agonist define the next incretin wave. An identity and receptor-target comparison of Mazdutide, Survodutide, and Retatrutide as research reference standards — with CAS numbers, mechanism class, and the verification each demands.
Published June 4, 2026 · 8 min read · By Lyochem Regulatory Team
The first incretin reference standards were GLP-1 mono-agonists. The next wave engages more than one receptor at once: Mazdutide and Survodutide are GLP-1 / glucagon dual agonists, and Retatrutide is a GIP / GLP-1 / glucagon tri-agonist. For a research lab building a metabolic-pharmacology panel, these three are frequently sourced together as a receptor-coverage series, and each carries its own identity and analytical-verification demands.
How do Mazdutide, Survodutide, and Retatrutide differ as research standards?
They differ by which receptors they engage and by molecular design. Mazdutide (CAS 2252403-56-6) is a long-acting oxyntomodulin-derived GLP-1 / glucagon (GCGR) dual agonist. Survodutide (CAS 2365457-03-9) is a GLP-1 / glucagon dual agonist designed with a GLP-1-receptor bias. Retatrutide (CAS 2381089-83-2) is a 39-residue GIP / GLP-1 / glucagon tri-agonist built on a GIP backbone with non-coded residues (Aib substitutions) and a fatty-diacid albumin-binding chain. All three are supplied strictly as research reference standards and verified by RP-HPLC purity plus ESI-MS identity per lot, with LC-MS/MS sequence confirmation recommended for first-lot qualification of these longer, multiply-modified peptides.
Identity and mechanism reference
| Peptide | CAS | Receptor target | Design / program code |
|---|---|---|---|
| Mazdutide | 2252403-56-6 | GLP-1 / glucagon (dual) | Oxyntomodulin analog (IBI362 / LY3305677) |
| Survodutide | 2365457-03-9 | GLP-1 / glucagon (dual) | GLP-1-biased dual agonist (BI 456906) |
| Retatrutide | 2381089-83-2 | GIP / GLP-1 / glucagon (tri) | 39 aa, GIP-backbone (LY3437943) |
Retatrutide and the two dual agonists are investigational; their precise formula and salt mass are best read from the lot COA rather than a single catalog value. Every Lyochem lot confirms identity by ESI-MS against the theoretical mass for the supplied form and reproduces the value on the batch COA so it can be cited directly in a methods section.
A receptor-coverage progression
These molecules extend the mono-agonist series into multi-receptor territory and form a useful pharmacology progression for a panel:
- GLP-1 + glucagon (dual). Both Mazdutide and Survodutide add glucagon-receptor agonism to GLP-1 agonism. Mazdutide is described in the literature as an oxyntomodulin analog — oxyntomodulin is the endogenous peptide that naturally engages both GLP-1 and glucagon receptors. Survodutide is described as deliberately GLP-1-biased in its dual activity.
- GIP + GLP-1 + glucagon (tri). Retatrutide adds a third arm, GIP-receptor agonism, on top of the GLP-1 / glucagon pair, making it the first tri-agonist in this group.
In the published metabolic-development literature, adding glucagon-receptor agonism is associated with effects on energy expenditure and hepatic-fat handling beyond the GLP-1 arm alone, and the GIP arm in the tri-agonist is studied for its additional contribution. For a research lab, this context explains why the three are studied side by side as a receptor-coverage series — it is not a claim about the reagent, and Lyochem makes no therapeutic representation about any of these standards.
Why these need deeper verification
All three are long and multiply modified — non-coded residues (Aib), backbone substitutions, and a fatty-diacid albumin-binding chain in the tri-agonist. A longer, more modified solid-phase synthesis produces more closely-related deletion, incomplete-modification, and aspartimide by-products that co-elute near the target peak on RP-HPLC and cannot be separated by intact mass alone. That is the core reason mass spec is necessary but not sufficient: ESI-MS confirms the molecular weight matches theory; it does not confirm residue order or modification placement, and isobaric substitutions can pass a mass check while still being wrong for a sequence-sensitive assay. For first-lot qualification of any of the three, request the LC-MS/MS b/y-ion ladder demonstrating the synthesized sequence matches the labelled sequence.
Counter-ion, water, and endotoxin
For all three, the practical handling questions are the same as for the rest of the incretin class: counter-ion form (acetate by default; TFA suppresses some cell-based readouts), water content by Karl Fischer (which affects the true peptide mass per vial), and lyophilized stability at minus 20 degrees Celsius protected from light. For in vivo metabolic-model work, request bacterial endotoxin (LAL) on the specific lot.
Sourcing scale and framing
Lyochem supplies Mazdutide, Survodutide, and Retatrutide as reference-grade research standards at milligram scale, characterized lot-by-lot, and labelled strictly Research Use Only. These are investigational compounds in the clinical-development program; the material supplied here is a research reagent, not a finished dosage form, and buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market. Because these are investigational, request the per-lot COA with the formula and salt mass for the specific batch before committing to a quantitative dosing calculation.
Talk to our regulatory team
Building a multi-receptor incretin panel?
Send the molecules, target purity, intended assay, and whether this is first-lot qualification. Lyochem will map the analytical packet across the panel before quote.
Frequently asked questions
- What receptors do Mazdutide, Survodutide, and Retatrutide target?
- Mazdutide (CAS 2252403-56-6) is a GLP-1 / glucagon dual agonist derived from oxyntomodulin. Survodutide (CAS 2365457-03-9) is a GLP-1 / glucagon dual agonist designed with a GLP-1-receptor bias. Retatrutide (CAS 2381089-83-2) is a 39-residue GIP / GLP-1 / glucagon tri-agonist. They form a receptor-coverage progression from dual to triple incretin/glucagon agonism.
- Why do these next-generation incretins need LC-MS/MS sequence verification?
- They are long and multiply modified — non-coded Aib residues, backbone substitutions, and a fatty-diacid albumin-binding chain in the tri-agonist. A longer, more modified synthesis produces closely-related deletion and incomplete-modification by-products that co-elute near the target on RP-HPLC and cannot be separated by intact mass alone. The LC-MS/MS b/y-ion ladder confirms residue order and modification placement, which is why it is recommended for first-lot qualification.
- Should I trust the catalog molecular weight for these investigational peptides?
- For Retatrutide, Survodutide, and Mazdutide, read the precise formula and salt mass from the batch COA for the specific lot rather than a single catalog value. They are investigational compounds whose supplied salt form and exact mass are best confirmed per batch before a quantitative dosing calculation. The ESI-MS identity on each Lyochem lot is reported against the theoretical mass for the supplied form.
- Are these next-generation incretin standards approved drugs?
- They are investigational compounds in the clinical-development program, supplied here as research reference standards for Research Use Only at milligram scale, characterized lot-by-lot. The material is a research reagent, not a finished dosage form and not labelled for human administration. Buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.